Company intelligence / Profile preview

SemaThera Inc.

Ownership: Private
Development stage: Other

Overview

SemaThera’s biological traps have demonstrated in vivo efficacy in orthologous models of retinal vascular diseases by binding and neutralizing SEMA3A. This results in reduced avascular areas through promoting physiological revascularization, decreased retinal vascular leakage, and reduced inflammation[1].

Therapeutic areas: Ophthalmology
Modalities: Biological traps / biologics targeting proteins such as Semaphorin 3A (SEMA3A)
Industry: Biotech

Drug pipeline

2 assets

ST-102

Preclinical

1 more asset in the full pipeline.

Partnerships

Roche — multi-year research collaboration and exclusive license agreement focused on developing anti-SEMA3A biologics for diabetic retinopathy and other ischemic retinal diseases[2][4].

Beyond the preview

Go deeper on SemaThera Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SemaThera Inc..